Martindale Pharma improves Aurum pre-filled syringe packaging

Published: 9-Nov-2011
Packaging Regulatory

To ensure ease of use and improve patient safety

Martindale Pharma improves Aurum pre-filled syringe packaging
Martindale Pharma, a UK manufacturer and supplier of pharmaceutical specials, has made a number of improvements to its Aurum range of 11 pre-filled syringes.

The Aurum syringes are used for on-the-spot administration of drugs where high visibility and simple drug identification is crucial.

The Brentwood, Essex-based firm has redesigned the range to enhance ease of use and help improve patient safety. Specific improvements include new colour-differentiated packaging; colour-differentiated translucent boxes that confirm contents; and colour-differentiated labels. In addition the firm has improved tamper-evident labels and the packaging is latex-free and Luer Lock fitting.

The firm says its new colour-differentiated packaging meets national and international colour differentiation standards on syringe labelling and also the Royal College of Anaesthetists recommendations on syringe labelling in critical care.

See more

You may also like

Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

Read more
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    UK Budget 2026: what it means for pharma manufacturing VAT relief on free medicines, £1bn in new investment and revised capital allowances give pharma manufacturers progress — but gaps remain
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I) Documentation Specialist Snehal Godse explains why unit-level FAT and SAT leave critical multivendor interfaces unverified and proposes a risk-based framework to qualify product transfers, control signals, interlocks, sensors and shared utilities
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Embracing healthcare innovation with 2D codes Pharmaceutical manufacturers already serialise medicines using 2D codes to meet regulatory requirements, but a 2D code can be so much more than a tick box for compliance, explains Ian Chapman, Strategic Manager for Digital Coding at Domino Printing Sciences
  4. Why CAPA keeps failing and what strong organisations do differently This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk

You may also like

Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
You need to be a subscriber to read this article.
Click here to find out more.
Packaging
Embracing healthcare innovation with 2D codes

Embracing healthcare innovation with 2D codes

Pharmaceutical manufacturers already serialise medicines using 2D codes to meet regulatory requirements, but a 2D code can be so much more than a tick box for compliance, explains Ian Chapman, Strategic Manager for Digital Coding at Domino Printing Sciences
Manufacturing
Pace Life Sciences completes EMA GMP inspection at New Jersey CDMO facility

Pace Life Sciences completes EMA GMP inspection at New Jersey CDMO facility

The inspection supports renewal of the EU GMP certificate at the company's New Jersey site, which provides pharmaceutical analytical testing, microbiology and development services
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
UK Budget 2026: what it means for pharma manufacturing

UK Budget 2026: what it means for pharma manufacturing

VAT relief on free medicines, £1bn in new investment and revised capital allowances give pharma manufacturers progress — but gaps remain
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
A completed reply is not a finalised case: how to test AI intake in pharma

A completed reply is not a finalised case: how to test AI intake in pharma

A medical information response marked complete says nothing about safety information that arrives later. Before accepting an AI intake demonstration, ask to see what happens to the next message: who assesses it, what stays pending and which dates are preserved
You need to be a subscriber to read this article.
Click here to find out more.
Packaging
PPWR: why interpretation and alignment matter more than awareness

PPWR: why interpretation and alignment matter more than awareness

The EU Packaging and Packaging Waste Regulation is often described as a packaging regulation. For pharmaceutical manufacturers, however, its implications extend well beyond packaging alone
Manufacturing
Stevanato Group and Aptar Pharma collaborate to accelerate prefilled syringe system selection

Stevanato Group and Aptar Pharma collaborate to accelerate prefilled syringe system selection

Joint system-level testing combines Stevanato's glass syringes with Aptar's elastomer components to provide key data earlier in development and inform packaging decisions for sensitive biologics and other injectable therapies
Subscribe now